Goldman Sachs Group Inc Logic Bio Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$0.35 - $0.74 $4,304 - $9,100	12,298 New	12,298 $4,000
Q2 2022 Aug 15, 2022	SELL	$0.35 - $0.74 $173,562 - $366,960	-495,892 Reduced 97.58%	12,298 $4,000
Q1 2022 May 16, 2022	SELL	$0.61 - $2.49 $173 - $709	-285 Reduced 0.06%	508,190 $346,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.53 $1.03 Million - $2.11 Million	466,289 Added 1105.32%	508,475 $1.18 Million
Q3 2021 Nov 10, 2021	BUY	$3.85 - $5.09 $162,416 - $214,726	42,186 New	42,186 $193,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.